Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Seniprutug is a biosimilar that functions as an antagonist to TRBV9, a protein associated with T cell receptor beta variable 9, playing a crucial role in adaptive immune responses and receptor-mediated signaling pathways. TRBV9 is localized at the cell membrane and consists of 114 amino acid residues with a molecular weight of approximately 12.6 kilodaltons. The biosimilar Seniprutug, first developed by Biocad CJSC, is currently undergoing phase 3 trials and targets immune system diseases such as non-radiographic axial spondyloarthritis. Seniprutug is utilized as both a therapeutic agent and as research grade material, aiding in the immunodetection of TRBV9 for various studies in immunology, particularly in conditions affecting the skin, musculoskeletal, and infectious disease domains.
仅用于科研。不用于诊断过程。未经明确授权不得转售。